OBD
NEUTRALOxford BioDynamics Provides Update on EpiSwitch PSE Test
The diagnostics company provides an update on its EpiSwitch PSE test, noting continued sales growth in the US and UK private healthcare market.
Oxf BioDynamics
0.2600GBX
-1.89%
Market Cap
11.16M
Volume
25.07M
81% of avg
P/E Ratio
-8.67
EPS (TTM)
-0.03
Beta
-0.5
Day Range
0.2435p - 0.2600p
52 Week Range
0.2300p0.2600p1.6000p
0.2600p
Upcoming Events
Q1 2026
Potential Commercialization of CRC Test (Q1 2026)
High Impact Event
OBD
NEUTRALOxford BioDynamics Announces Shareholding Change
The diagnostics company has announced a change in shareholding, with Vulpes Investment Management Pte Ltd increasing its stake to 14.42%.
OBD
NEUTRALOxford BioDynamics Provides Regulatory Update
The healthcare diagnostics company has announced a regulatory filing regarding a change in shareholding.
OBD
NEUTRALOxford BioDynamics Plc Provides Regulatory Update
The diagnostics company has announced a regulatory filing regarding a change in shareholding.
OBD
NEUTRALOxford BioDynamics Plc Announces Holding(s) in Company
The healthcare diagnostics company has received a notification of a change in major shareholding.
OBD
NEUTRALOxford BioDynamics Plc Announces Holding(s) in Company
The healthcare diagnostics company has announced a change in major shareholding, with Unicorn Asset Management Limited now holding 12.86% of the voting rights.
OBD
NEUTRALOxford BioDynamics Grants Share Options to Directors and PDMRs
The diagnostics company has granted share options to its senior management team.
OBD
BADOxford BioDynamics Raises £7 Million Through Discounted Placing
The healthcare diagnostics company has raised £7 million through a discounted share placing, resulting in significant dilution for existing shareholders.
OBD
NEUTRALOxford BioDynamics Highlights Potential of EpiSwitch PSE in NHS Prostate Cancer Screening
The healthcare company reports on a new study that highlights the potential of its EpiSwitch PSE blood test to improve prostate cancer screening in the UK's National Health Service.
OBD
NEUTRALOxford BioDynamics and UEA Develop Breakthrough Diagnostic Test for Chronic Fatigue Syndrome
The healthcare company and university have developed a highly accurate blood test to diagnose the debilitating Chronic Fatigue Syndrome, offering hope for patients who have long lacked a reliable diagnostic tool.